Ivor

Bemiparin Sodium, the active ingredient in Ivor, is a low molecular weight heparin presented as a subcutaneous injection for anticoagulant use. It is employed to prevent and treat venous thromboembolism, including deep‑vein thrombosis, in surgical and medical patients.

GNH USA supplies Ivor as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality assurance, regulatory compliance and reliable logistics for global distribution.

Bemiparin Sodium is indicated for anticoagulation in conditions related to venous thromboembolism.

- Prevention of venous thromboembolism in surgical patients: reduces the risk of postoperative deep‑vein thrombosis and pulmonary embolism. - Treatment and secondary prevention of deep vein thrombosis: helps resolve existing clots and prevents recurrence. - Prevention of thromboembolic complications in medical patients: lowers incidence of clot formation in immobilized or high‑risk medical populations.

Bemiparin Sodium may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Injection site erythema: redness or mild irritation at the subcutaneous site. - Minor bruising: small hematomas around the injection area. - Nausea: transient feeling of stomach upset. - Headache: mild to moderate head discomfort.

Serious or Rare Side Effects: - Major bleeding: gastrointestinal, intracranial or severe hemorrhage. - Thrombocytopenia: significant drop in platelet count, potentially leading to bleeding. - Allergic reaction: urticaria, angioedema or anaphylaxis.

When prescribing Bemiparin Sodium, clinicians should consider several safety precautions to minimize risk. - Renal impairment: adjust use or monitor closely in patients with reduced kidney function. - Active bleeding: avoid in patients with ongoing hemorrhage or recent major surgery. - Concomitant anticoagulants: use caution when combined with other anticoagulant or antiplatelet agents. - Pregnancy: assess risk‑benefit ratio as safety data are limited. - Elderly patients: monitor for bleeding due to increased sensitivity. - Store at room temperature: keep in original container, protect from moisture and direct sunlight.

Bemiparin Sodium can interact with other medicines, influencing anticoagulant effect or bleeding risk.

Major Interactions (Avoid): - Warfarin: combined use markedly increases bleeding risk. - Direct oral anticoagulants (e.g., rivaroxaban, apixaban): additive anticoagulation may cause severe hemorrhage. - Thrombolytic agents: concurrent therapy can lead to uncontrolled bleeding.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may enhance mucosal bleeding. - Antiplatelet drugs (aspirin, clopidogrel): increase overall bleeding tendency. - Heparin products: overlapping anticoagulant activity requires dose adjustment.